Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-03-29 4:14 pm Purchase | 13D | ARS PHARMACEUTICALS, INC SPRY | RA CAPITAL MANAGEMENT L.P. | 10,860,977 11.3% | 1,401,299 (+14.81%) | View |
| 2024-02-09 08:35 am Sale | 13G | ARS PHARMACEUTICALS, INC SPRY | FMR LLC | 1,202,315 1.252% | -4,167,047 (-77.61%) | View |
| 2023-09-25 4:30 pm Purchase | 13D | ARS PHARMACEUTICALS, INC SPRY | RA CAPITAL MANAGEMENT L.P. | 9,459,678 9.9% | 2,700,000 (+39.94%) | View |
| 2023-09-01 4:15 pm Sale | 13D | ARS PHARMACEUTICALS, INC SPRY | Bell Robert G. | 4,313,965 4.5% | -4,250,000 (-49.63%) | View |
| 2023-08-31 5:25 pm Purchase | 13D | ARS PHARMACEUTICALS, INC SPRY | RA CAPITAL MANAGEMENT L.P. | 6,759,678 7.07% | 5,017,492 (+288.00%) | View |
| 2023-02-14 4:35 pm Unchanged | 13G | ARS PHARMACEUTICALS, INC SPRY | NEXTECH VI ONCOLOGY SCSP | 1,910,029 2% | 0 (Unchanged) | View |
| 2023-02-13 4:32 pm Purchase | 13G | ARS PHARMACEUTICALS, INC SPRY | K2 PRINCIPAL FUND L.P. | 2,045,348 2.2% | 138,730 (+7.28%) | View |
| 2023-02-09 08:23 am Purchase | 13G | ARS PHARMACEUTICALS, INC SPRY | FMR LLC | 5,369,362 5.726% | 1,615,625 (+43.04%) | View |
| 2022-11-30 4:23 pm Sale | 13D | ARS PHARMACEUTICALS, INC SPRY | ORBIMED ADVISORS LLC | 7,788,510 8.3% | -1 (-0.00%) | View |
| 2022-11-21 4:07 pm Purchase | 13D | ARS PHARMACEUTICALS, INC SPRY | Bell Robert G. | 8,563,965 9.1% | 8,563,965 (New Position) | View |
| 2022-11-18 5:06 pm Purchase | 13D | ARS PHARMACEUTICALS, INC SPRY | Flynn James E | 11,077,927 11.81% | 11,077,927 (New Position) | View |
| 2022-11-18 2:17 pm Purchase | 13D | ARS PHARMACEUTICALS, INC SPRY | Pratik Shah Living Trust dated June 15 2011 | 10,156,204 10.8% | 10,156,204 (New Position) | View |
| 2022-11-18 2:09 pm Purchase | 13D | ARS PHARMACEUTICALS, INC SPRY | Lowenthal Richard E | 7,422,432 7.9% | 7,422,432 (New Position) | View |
| 2022-11-18 1:58 pm Purchase | 13D | ARS PHARMACEUTICALS, INC SPRY | Tanimoto Sarina | 6,265,170 6.7% | 6,265,170 (New Position) | View |
| 2022-07-15 6:03 pm Purchase | 13G | ARS PHARMACEUTICALS, INC SPRY | K2 PRINCIPAL FUND L.P. | 1,906,618 5.41% | 1,906,618 (New Position) | View |
| 2022-02-14 4:33 pm Sale | 13G | ARS PHARMACEUTICALS, INC SPRY | Boxer Capital LLC | 0 0% | -1,675,377 (Position Closed) | View |
| 2022-02-14 4:11 pm Unchanged | 13G | ARS PHARMACEUTICALS, INC SPRY | RA CAPITAL MANAGEMENT L.P. | 1,742,186 4.97% | 0 (Unchanged) | View |
| 2022-02-14 1:38 pm Sale | 13G | ARS PHARMACEUTICALS, INC SPRY | EcoR1 Capital LLC | 1,060,010 3% | -1,473,625 (-58.16%) | View |
| 2022-02-10 5:58 pm Purchase | 13G | ARS PHARMACEUTICALS, INC SPRY | WASATCH ADVISORS LP | 1,775,690 5.1% | 1,775,690 (New Position) | View |
| 2022-02-09 10:24 am Sale | 13G | ARS PHARMACEUTICALS, INC SPRY | FMR LLC | 3,753,737 10.701% | -505,875 (-11.88%) | View |